{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T19:08:31Z","timestamp":1719774511849},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol Suppl"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11789-019-00098-0","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T01:29:46Z","timestamp":1551835786000},"page":"20-27","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipoprotein(a)\u2014an interdisciplinary challenge"],"prefix":"10.1007","volume":"14","author":[{"given":"U.","family":"Julius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tselmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"key":"98_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","volume":"59","author":"K Berg","year":"1963","unstructured":"Berg K (1963) A new serum type system in man\u2014the LP system. Acta Pathol Microbiol Scand 59:369\u2013382","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"14","key":"98_CR2","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0002-9149(96)00159-2","volume":"77","author":"G Assmann","year":"1996","unstructured":"Assmann G, Schulte H, von Eckardstein A (1996) Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77(14):1179\u20131184","journal-title":"Am J Cardiol"},{"issue":"1","key":"98_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1194\/jlr.R071571","volume":"58","author":"KM Kostner","year":"2017","unstructured":"Kostner KM, Kostner GM (2017) Lipoprotein (a): a\u00a0historical appraisal. J\u00a0Lipid Res 58(1):1\u201314. \n                    https:\/\/doi.org\/10.1194\/jlr.R071571","journal-title":"J Lipid Res"},{"issue":"2","key":"98_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0021-9150(96)06030-3","volume":"129","author":"P Cremer","year":"1997","unstructured":"Cremer P, Nagel D, Mann H, Labrot B, Muller-Berninger R, Elster H et al (1997) Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a\u00a0cohort of 5790 men. Atherosclerosis 129(2):221\u2013230","journal-title":"Atherosclerosis"},{"issue":"23","key":"98_CR5","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF et\u00a0al (2010) Lipoprotein(a) as a\u00a0cardiovascular risk factor: current status. Eur Heart\u00a0J 31(23):2844\u20132853. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehq386","journal-title":"Eur Heart J"},{"issue":"6","key":"98_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J\u00a0Am Coll Cardiol 69(6):692\u2013711. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042","journal-title":"J Am Coll Cardiol"},{"key":"98_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.atherosclerosissup.2015.02.038","volume":"18","author":"S Tselmin","year":"2015","unstructured":"Tselmin S, Muller G, Gelgaft E, Fischer S, Julius U (2015) An elevated lipoprotein(a) plasma level as a\u00a0cardiovascular risk factor. Atheroscler Suppl 18:257\u2013262. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2015.02.038","journal-title":"Atheroscler Suppl"},{"issue":"32","key":"98_CR8","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","volume":"38","author":"C Waldeyer","year":"2017","unstructured":"Waldeyer C, Makarova N, Zeller T, Schnabel RB, Brunner FJ, Jorgensen T et\u00a0al (2017) Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart\u00a0J 38(32):2490\u20132498. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx166","journal-title":"Eur Heart J"},{"issue":"7","key":"98_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","volume":"5","author":"S Zewinger","year":"2017","unstructured":"Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K et\u00a0al (2017) Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a\u00a0molecular and genetic association study. Lancet Diabetes Endocrinol 5(7):534\u2013543. \n                    https:\/\/doi.org\/10.1016\/S2213-8587(17)30096-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10155","key":"98_CR10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR et al (2018) Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 392(10155):1311\u20131320. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)31652-0","journal-title":"Lancet"},{"key":"98_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy902","author":"A Langsted","year":"2019","unstructured":"Langsted A, Kamstrup PR, Nordestgaard BG (2019) High lipoprotein(a) and high risk of mortality. Eur Heart\u00a0J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy902","journal-title":"Eur Heart J"},{"issue":"1","key":"98_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","volume":"30","author":"F Kronenberg","year":"2016","unstructured":"Kronenberg F (2016) Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther 30(1):87\u2013100. \n                    https:\/\/doi.org\/10.1007\/s10557-016-6648-3","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"98_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","volume":"71","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM et al (2018) NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J\u00a0Am Coll Cardiol 71(2):177\u2013192. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2017.11.014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"98_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2013","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG (2013) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J\u00a0Am Coll Cardiol 63(5):470\u2013477. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.09.038","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"98_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/00365513.2010.550311","volume":"71","author":"PR Kamstrup","year":"2011","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG (2011) Lipoprotein(a) and risk of myocardial infarction\u2014genetic epidemiologic evidence of causality. Scand J Clin Lab Invest 71(2):87\u201393. \n                    https:\/\/doi.org\/10.3109\/00365513.2010.550311","journal-title":"Scand J Clin Lab Invest"},{"key":"98_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2017.03.021","volume":"260","author":"S Li","year":"2017","unstructured":"Li S, Wu NQ, Zhu CG, Zhang Y, Guo YL, Gao Y et\u00a0al (2017) Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis 260:67\u201374. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.021","journal-title":"Atherosclerosis"},{"issue":"39","key":"98_CR17","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et\u00a0al (2016) 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart\u00a0J 37(39):2999\u20133058. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"issue":"2","key":"98_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/MOL.0000000000000392","volume":"28","author":"M Afshar","year":"2017","unstructured":"Afshar M, Thanassoulis G (2017) Lipoprotein(a): new insights from modern genomics. Curr Opin Lipidol 28(2):170\u2013176. \n                    https:\/\/doi.org\/10.1097\/MOL.0000000000000392","journal-title":"Curr Opin Lipidol"},{"key":"98_CR19","series-title":"BAnz.138:3321","volume-title":"Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Richtlinie Methoden vertrags\u00e4rztliche Versorgung: Apherese bei isolierter Lp(a)-Erh\u00f6hung","author":"Bundesministerium f\u00fcr Gesundheit","year":"2008","unstructured":"Bundesministerium f\u00fcr Gesundheit (2008) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Richtlinie Methoden vertrags\u00e4rztliche Versorgung: Apherese bei isolierter Lp(a)-Erh\u00f6hung. BAnz.138:3321"},{"key":"98_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11789-019-00099-z","author":"U Julius","year":"2019","unstructured":"Julius U, Tselmin S, Schatz U, Fischer S, Bornstein SR (2019) Lipoprotein(a) and proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors. Clin Res Cardiol Suppl. \n                    https:\/\/doi.org\/10.1007\/s11789-019-00099-z","journal-title":"Clin. Res. Cardiol. Suppl."},{"issue":"3","key":"98_CR21","first-page":"229","volume":"6","author":"BR Jaeger","year":"2009","unstructured":"Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E et\u00a0al (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6(3):229\u2013239","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"24","key":"98_CR22","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D et al (2013) Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128(24):2567\u20132576","journal-title":"Circulation"},{"key":"98_CR23","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","volume":"26","author":"E Roeseler","year":"2016","unstructured":"Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P et al (2016) Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apo(a) characterization. Arterioscler Thromb Vasc Biol 26:2019\u20132027. \n                    https:\/\/doi.org\/10.1161\/ATVBAHA.116.307983","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"98_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","volume":"14","author":"M Dryander von","year":"2013","unstructured":"von Dryander M, Fischer S, Passauer J, Muller G, Bornstein SR, Julius U (2013) Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 14(1):39\u201344. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.005","journal-title":"Atheroscler Suppl"},{"key":"98_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.atherosclerosissup.2015.02.034","volume":"18","author":"U Emmrich","year":"2015","unstructured":"Emmrich U, Hohenstein B, Julius U (2015) Actual situation of lipoprotein apheresis in Saxony in 2013. Atheroscler Suppl 18:215\u2013225. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2015.02.034","journal-title":"Atheroscler Suppl"},{"key":"98_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.atherosclerosissup.2017.05.047","volume":"30","author":"U Schatz","year":"2017","unstructured":"Schatz U, Tselmin S, Muller G, Julius U, Hohenstein B, Fischer S et\u00a0al (2017) Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels\u2014A multicenter observational study. Atheroscler Suppl 30:246\u2013252. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.047","journal-title":"Atheroscler Suppl"},{"key":"98_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd5020027","author":"U Julius","year":"2018","unstructured":"Julius U (2018) Current role of lipoprotein apheresis in the treatment of high-risk patients. J\u00a0Cardiovasc Dev Dis. \n                    https:\/\/doi.org\/10.3390\/jcdd5020027","journal-title":"J Cardiovasc Dev Dis"},{"issue":"10002","key":"98_CR28","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF et al (2015) Antisense therapy targeting apolipoprotein(a): a\u00a0randomised, double-blind, placebo-controlled phase 1 study. Lancet 386(10002):1472\u20131483. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)61252-1","journal-title":"Lancet"},{"issue":"10057","key":"98_CR29","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388(10057):2239\u20132253. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)31009-1","journal-title":"Lancet"},{"issue":"1","key":"98_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","volume":"12","author":"SM Marcovina","year":"2018","unstructured":"Marcovina SM, Viney NJ, Hughes SG, Xia S, Witztum JL, Tsimikas S (2018) Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. J\u00a0Clin Lipidol 12(1):122\u2013129.e2. \n                    https:\/\/doi.org\/10.1016\/j.jacl.2017.10.024","journal-title":"J Clin Lipidol"},{"issue":"1","key":"98_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1871529X17666170421150028","volume":"17","author":"Z Mazhar","year":"2017","unstructured":"Mazhar Z, Hughes A, Garelnabi M (2017) Targeting the role of lipoprotein (a) in stroke. Cardiovasc Hematol Disord Drug Targets 17(1):64\u201372. \n                    https:\/\/doi.org\/10.2174\/1871529X17666170421150028","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"1","key":"98_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/ijs.12136","volume":"9","author":"SM Sultan","year":"2014","unstructured":"Sultan SM, Schupf N, Dowling MM, Deveber GA, Kirton A, Elkind MS (2014) Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke. Int J Stroke 9(1):79\u201387. \n                    https:\/\/doi.org\/10.1111\/ijs.12136","journal-title":"Int J Stroke"},{"issue":"2","key":"98_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jjcc.2012.09.009","volume":"61","author":"AE Fanshawe","year":"2013","unstructured":"Fanshawe AE, Ibrahim M (2013) The current status of lipoprotein (a) in pregnancy: a\u00a0literature review. J\u00a0Cardiol 61(2):99\u2013106. \n                    https:\/\/doi.org\/10.1016\/j.jjcc.2012.09.009","journal-title":"J Cardiol"},{"issue":"3","key":"98_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3329\/bmrcb.v36i3.7289","volume":"36","author":"S Parvin","year":"2010","unstructured":"Parvin S, Samsuddin L, Ali A, Chowdhury SA, Siddique I (2010) Lipoprotein (a) level in pre-eclampsia patients. Bangladesh Med Res Counc Bull 36(3):97\u201399","journal-title":"Bangladesh Med Res Counc Bull"},{"issue":"5","key":"98_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/ckj\/sfu083","volume":"7","author":"VJ Schettler","year":"2014","unstructured":"Schettler VJ, Schulz EG, Hagenah GC, Neumann CL (2014) Successful completion of pregnancy using apheresis and a\u00a0balanced dose of coagulation factors in the presence of high thrombophilia and Lp(a) levels in a\u00a0woman with two previous abortions. Clin Kidney\u00a0J 7(5):497\u2013498. \n                    https:\/\/doi.org\/10.1093\/ckj\/sfu083","journal-title":"Clin Kidney J"},{"issue":"5","key":"98_CR36","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.fertnstert.2016.01.014","volume":"105","author":"I Romagnuolo","year":"2016","unstructured":"Romagnuolo I, Sticchi E, Attanasio M, Grifoni E, Cioni G, Cellai AP et al (2016) Searching for a\u00a0common mechanism for placenta-mediated pregnancy complications and cardiovascular disease: role of lipoprotein(a). Fertil Steril 105(5):1287\u20131293.e3. \n                    https:\/\/doi.org\/10.1016\/j.fertnstert.2016.01.014","journal-title":"Fertil Steril"},{"issue":"7","key":"98_CR37","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/BF00207478","volume":"72","author":"U Julius","year":"1994","unstructured":"Julius U, Fritsch H, Fritsch W, Rehak E, Fucker K, Leonhardt W et\u00a0al (1994) Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women. Clin Investig 72(7):502\u2013507","journal-title":"Clin Investig"},{"issue":"3","key":"98_CR38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/clc.22880","volume":"41","author":"KL Ellis","year":"2018","unstructured":"Ellis KL, Pang J, Chieng D, Bell DA, Burnett JR, Schultz CJ et\u00a0al (2018) Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. Clin Cardiol 41(3):378\u2013384. \n                    https:\/\/doi.org\/10.1002\/clc.22880","journal-title":"Clin Cardiol"},{"key":"98_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.atherosclerosissup.2017.05.014","volume":"30","author":"F Heigl","year":"2017","unstructured":"Heigl F, Pflederer T, Schettler V, Grutzmacher P, Julius U, Ringel J et\u00a0al (2017) Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism. Atheroscler Suppl 30:63\u201371. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.014","journal-title":"Atheroscler Suppl"}],"container-title":["Clinical Research in Cardiology Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-019-00098-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11789-019-00098-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11789-019-00098-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:15:21Z","timestamp":1583280921000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11789-019-00098-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":39,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1007\/s11789-019-00098-0","relation":{},"ISSN":["1861-0706","1861-0714"],"issn-type":[{"value":"1861-0706","type":"print"},{"value":"1861-0714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"5 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"U.\u00a0Julius: honoraria from Aegerion, Akcea, Amgen, Amryt, Chiesi, Sanofi, Kaneka, Diamed, Fresenius Medical Care, MSD. S.\u00a0Tselmin: received honoraria for lectures and consulting by Amgen, Fresenius Medical Care, Kaneka, MSD, and Sanofi-Aventis. U.\u00a0Schatz: No conflicts of interest relevant to this publication. S.\u00a0Fischer: honoraria from Sanofi, Amgen, MSD, Berlin-Chemie, Abbott, Boehringer Ingelheim. S.R.\u00a0Bornstein declare that he has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}